Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
The present invention discloses nucleic acids, proteins, and antibodies for SALL4 (including isoforms SALL4A, SALL4B, and SALL4C), a zinc finger transcriptional factor. Further, methods are disclosed which demonstrate that constitutive expression of SALL4 increases leukemogenic potential in cells of model animal systems. Moreover, constitutive expression of select isoforms (e.g., SALL4B) in transgenic mice demonstrate that these animals develop myelodysplastic syndrome (MDS)-like signs and symptoms, including subsequent acute myeloid leukemia (AML), which is transplantable. The disclosure also provides methods for identifying and purifying embryonic stem cells, adult stem cells, cancer stem cells, including leukemia stem cells, methods for identifying substances which bind to and/or modulate SALL4, methods for diagnosing MDS in a subject, and methods of treating a subject presenting MDS.
1. A method of diagnosing a myelodysplastic syndrome (MDS) in a subject comprising:
(a) providing a biological sample from the subject;
(b) contacting the biological sample with an antibody which binds to a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6; and
(c) detecting the binding of the antibody to the sample,
wherein detecting binding correlates with MDS.
2. A method of diagnosing acute myeloid leukemia (AML) in a subject comprising:
(a) providing a biological sample from the subject;
(b) contacting the biological sample with an antibody which binds to a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6; and
(c) detecting the binding of the antibody to the sample,
wherein detecting binding correlates with AML.
3. The method of claim 2 , wherein the polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 2.
4. The method of claim 2 , wherein the polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 4.
5. The method of claim 2 , wherein the polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 6.